Modi Challenges Indian Pharma to Join Global Top 5
By Business Desk
PM Modi urges Indian pharma companies to break into the global top 5, aiming to boost the sector’s $130B potential by 2030.
Prime Minister Narendra Modi has urged Indian pharmaceutical companies to achieve a place among the top five global firms. This ambition aims to significantly elevate the country’s standing in the international pharma landscape.
India’s pharmaceutical sector currently holds the third position worldwide by volume and eleventh by value. The domestic market is projected to expand substantially from $60 billion to $130 billion by 2030, reflecting significant growth potential.
India’s Pharmaceutical Footprint
Over 3,000 businesses currently operate within India’s pharma sector, supported by 10,500 manufacturing facilities. The nation is a critical global supplier of generic medications, contributing approximately 20% to the world’s supply.
India offers 60,000 generic products across 60 therapeutic categories. Its pharmaceutical exports reached $30.5 billion in 2024–2025, marking a significant increase from $1.9 billion recorded in 2000–01.
A substantial 50% of these exports are directed towards highly regulated markets, including the United States and Europe. This highlights the international acceptance and quality standards of Indian pharmaceuticals.
Despite these achievements, no Indian pharmaceutical company has yet secured a spot among the global top five. Major players like Sun Pharmaceutical Industries Ltd., a top generic drug producer, reportedly have plans for significant acquisitions to enhance their global ranking.
Modi’s directive underscores a national ambition to solidify India’s status as a global pharmaceutical powerhouse. This move extends beyond its current strengths in sheer volume and generic drug supply, aiming for leadership in value.